Кудайбергенова А. Г. ¹, Белова А. Р. ¹, Горбань Н. А.²

¹ФГБУ «Научно-исследовательский институт онкологии им. Н. Н. Петрова» Минздрава России; Россия, 197758 Санкт-Петербург, п. Песочный, ул. Ленинградская, 68;

²Медицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России; Россия, 249036 Обнинск, ул. Королева, 4

1. SEER data base [Electronic resource]. Available at: https://seer. cancer.gov/ (accessed: 13.03.2025).

2. Семиглазов В.Ф., Палтуев Р.М., Семиглазов В.В. и др. Ранний рак молочной железы: прогностическое значение биологических подтипов (анализ кумулятивной базы данных ФГБУ НИИ онкологии им. Н.Н. Петрова» Минздравсоцразвития. Злокачественные опухоли 2012;2(2):12–8. Semiglazov V.F., Paltuev R.M., Semiglazov V.V. et al. Early breast cancer: prognostic value of biological subtypes (analysis of the cumulative database of the Petrov Research Institute of Oncology. Zlokachestvennye opukholi = Malignant Tumours 2012;2(2):12–8. (In Russ.).

3. Пожарисский К.М., Леенман Е.Е. Значение иммуногистохимических методик для определения характера лечения и прогноза опухолевых заболеваний. Архив патологии 2000;62(5):3–11. Pozharissky K.M., Leenman E.E. Significance of immunohistochemical methods to determine treatment and prognosis of tumour diseases. Arhiv patologii = Archives of Pathology 2000;62(5):3–11. (In Russ.).

4. Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177–82. DOI: 10.1126/science.3798106

5. Wolff A.C., Hammond M.E.H., Schwartz J.N. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131(1):18–43. DOI: 10.5858/2007-131-18-ASOCCO

6. Couturier J., Vincent-Salomon A., Nicolas A. et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Modern Pathol 2000;13(11):1238–43. DOI: 10.1038/modpathol.3880228

7. Lebeau A., Deimling D., Kaltz C. et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19(2):354–63. DOI: 10.1200/JCO.2001.19.2.354

8. Wolff A.C., Hammond M.E. H., Hicks D.G. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138(2):241–56. DOI: 10.5858/arpa.2013-0953-SA

9. Wolff A.C., Hammond M.E. H., Allison K.H. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med 2018;142(11):1364–82. DOI: 10.5858/arpa.2018-0902-SA

10. Gordian-Arroyo A.M., Zynger D.L., Tozbikian G.H. Impact of the 2018 ASCO/CAP HER2 guideline focused update. Am J Clin Pathol 2019;152(1):17–26. DOI: 10.1093/ajcp/aqz012

11. Xu B., Shen J., Guo W. et al. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer. Pathol Res Pract 2019;215(2):251–5. DOI: 10.1016/j.prp.2018.10.035

12. Crespo J., Sun H., Wu J. et al. Rate of reclassification of HER2- equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS One 2020;15(11):e0241775. DOI: 10.1371/journal.pone.0241775

13. Семиглазов В.Ф. Клинико-патогенетические формы рака мо- лочной железы (новые подходы к планированию лечения). Хирургия. Журнал им. Н.И. Пирогова 1980;12:27–30. Semiglazov V.F. Clinical and pathogenetic forms of breast cancer (new approaches to treatment planning). Khirurgiya. Zhurnal im. N. I. Pirogova = Surgery. N.I. Pirogov Journal 1980;12:27–30. (In Russ.).

14. Moeder C.B., Giltnane J.M., Harigopal M. et al. Quantitative justification of the change from 10 % to 30 % for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: Tumor heterogeneity in breast cancer and its implications for tissue microarray-based assessment of outcome. J Clin Oncol 2007;25(34):5418–25. DOI: 10.1200/JCO.2007.12.8033

15. Vance G.H., Barry T.S., Bloom K.J. et al. Genetic heterogeneity in HER2 testing in breast cancer panel summary and guidelines. Arch Pathol Lab Med 2009;133(4):611–2. DOI: 10.5858/133.4.611

16. Walker R.A., Bartlett J.M.S., Dowsett M. et al. HER2 testing in the UK: Further update to recommendations. J Clin Pathol 2008;61(7):818–24. DOI: 10.1136/jcp.2007.054866

17. Starczynski J., Atkey N., Connelly Y. et al. HER2 gene amplification in breast cancer – a rogues’ gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol 2012;137(4):595–605. DOI: 10.1309/AJCPATBZ2JFN1QQC

18. Lee H.J., Seo A.N., Kim E.J. et al. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. Am J Clin Pathol 2014;142(6):755–66. DOI: 10.1309/AJCPIRL4GUVGK3YX

19. Seol H., Lee H.J., Choi Y. et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 2012;25(7):938–48. DOI: 10.1038/modpathol.2012.36

20. Lee H.J., Kim J.Y., Park S.Y. et al. Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab. Am J Clin Pathol 2015;144(4):570–8. DOI: 10.1309/AJCP51HCGPOPWSCY

21. Hou Y., Nitta H., Wei L. et al. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Res Treat 2017;166(2):447–57. DOI: 10.1007/s10549-017-4453-8